Zydus Lifesciences has announced the launch of VaxiFlu-4, India's first flu vaccine for the 2025 influenza season, designed as per the World Health Organization (WHO) recommended quadrivalent composition. This initiative aims to strengthen public health efforts by providing enhanced protection against multiple influenza strains.
The Quadrivalent Inactivated Influenza Vaccine (QIV), VaxiFlu-4, has been developed to provide broader immunity by targeting both influenza A and influenza B strains. The vaccine is designed to protect against:
A/Victoria/4897/2022 (H1N1) pdm09-like virus
A/Croatia/10136RV/2023 (H3N2)-like virus
B/Austria/1359417/2021 (B/Victoria lineage)-like virus
B/Phuket/3073/2013 (B/Yamagata lineage)-like virus
By covering a comprehensive range of influenza strains, VaxiFlu-4 minimizes the risk of vaccine mismatch and provides more effective protection compared to traditional trivalent vaccines. The vaccine has also been approved by India's Central Drug Laboratory (CDL), ensuring compliance with safety and efficacy standards.
VaxiFlu-4 is being marketed under Zydus Vaxxicare, a specialized division within Zydus Lifesciences, dedicated to preventive healthcare solutions. The vaccine was developed at the Vaccine Technology Centre (VTC) in Ahmedabad, which is known for its expertise in researching, developing, and manufacturing safe and effective vaccines.
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, emphasized the importance of preventive healthcare in tackling public health challenges. He stated,
"Preventive vaccines play a crucial role in enhancing public health worldwide. In India, the need for affordable, high-quality vaccines is critical in addressing major healthcare concerns. VaxiFlu-4 aligns with our mission of annual immunization to prevent flu outbreaks and protect lives."
Influenza has become a significant public health concern due to its seasonal outbreaks and unpredictable mutations. The flu virus spreads primarily through:
Airborne respiratory droplets from coughing and sneezing
Direct contact with infected surfaces or individuals
Influenza can lead to mild to severe illnesses and, in some cases, hospitalization or death, especially in high-risk populations such as:
Children under five years old
Elderly individuals
People with chronic diseases or weakened immune systems
The best way to prevent influenza and its severe complications is through annual flu vaccination. According to the World Health Organization (WHO), seasonal influenza causes between 290,000 to 650,000 deaths worldwide every year.
Regular flu vaccination can:
Reduce the spread of the virus
Lower hospitalization rates
Protect vulnerable populations
Enhance community immunity
With the launch of VaxiFlu-4, Zydus Lifesciences is committed to strengthening India’s immunization efforts by making influenza vaccines more accessible and affordable. The company aims to support national and global initiatives in flu prevention, ensuring a healthier future for all.
Conclusion: A Step Towards Better Flu Protection in India
The introduction of VaxiFlu-4 marks a significant advancement in India's influenza prevention strategies. As the country continues to battle seasonal flu outbreaks, timely vaccination remains a critical defense against the disease. Zydus Lifesciences' innovative approach ensures that people receive comprehensive protection, reinforcing the importance of annual immunization in safeguarding public health.